Water-soluble polysaccharides of Ganoderma lucidum (W.Curt.:Fr.) P. Karst. (Aphyllophoromycetideae) alleviate the dose-limiting toxicities of irinotecan (CPT-11)

International Journal of Medicinal Mushrooms

Volumn 8, Issue 4, 2006, Pages 321-327

  Hu, Zeping ^a   Chen, Xiao ^b   Yang, Xiaoxia ^b   Gao, Yihuai ^c   Zhou, Shufeng ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SUN YAT SEN UNIVERSITY   (China)

^c MASSEY UNIVERSITY   (New Zealand)

Author keywords

Diarrhea; Ganoderma lucidum; Irinotecan (CPT 11); Myelosuppression; Polysaccharide

Indexed keywords

GANODERMA LUCIDUM EXTRACT; GANOPOLY; IRINOTECAN; POLYSACCHARIDE; UNCLASSIFIED DRUG;

ACUTE DIARRHEA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL MONITORING; BLOOD CELL COUNT; BODY WEIGHT; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; DRUG CYTOTOXICITY; GANODERMA LUCIDUM; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALE; NEUTROPENIA; NONHUMAN; RAT; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT REDUCTION;

GANODERMA LUCIDUM; RATTUS;

EID: 33846673127     PISSN: 15219437     EISSN: None     Source Type: Journal    
DOI: 10.1615/IntJMedMushr.v8.i4.30     Document Type: Article

References (25)

1. Alsop R. M. and Vlachogiannis G. J. 1982. Determination of the molecular weight of clinical dextrans by gel permeation chromatography on TSK PW type columns. J Chromatogr, 246, 227-240.
2. Dische Z. 1947. A new specific color reaction of hexuronic acids. J Biol Chem, 167, 189-198.
3. Dubois M., Gilles K. A., Hamilton J. K., Rebers P. A., and Smith F. 1956. Colorimetric method for determination of sugar and related substances. Anal Chem, 28, 350-356.
4. Gandia D., Abigerges D., Armand J. P., Chabot G., Da Costa L., De Forni M., Mathieu-Boue A., and Herait P. 1993. CPT-11-induced cholinergic effects in cancer patients. J Clin Oncol, 11, 196-197.
5. Gao Y., Zhou S., Wen J., Huang M., and Xu A. 2002. Mechanism of the antiulcerogenic effect of Ganoderma lucidum polysaccharides on indomethacin-induced lesions in the rat. Life Sci, 72, 731-745.
6. Gao Y.H., Zhou S. F., Huang M., Lan J., and Gao H. 2002. Mechanisms for the protective effects of Ganoderma lucidum polysaccharide fraction on indomethacin-induced ulcer in the rat. Life Sci, 72, 731-745.
7. Ghezzi P. C. A. 2004. Tumor necrosis factor as a pharmacological target. Methods Mol Med., 98, 1-8.
8. Goldwasser F., Shimizu T., Jackman J., Hoki Y., O'Connor P. M., Kohn K. W., and Pommier Y. 1996. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res., 56, 4430-4437.
9. Gupta E., Lestingi T. M., Mick R., Ramirez J., Vokes E. E., and Ratain M. J. 1994. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res, 54, 3723-3725.
10. Hu Z. P., Yang X. X., Ho P. C., Chan E., Chan S. Y., Xu C. J., Li X. T., Zhu Y. Z., Duan W., Chen X., Huang M., Yang H. Y., and Zhou S. F. 2005. St. John's wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats. Pharm Res, 22, 902-914.
11. Kawato Y., Aonuma M., Hirota Y., Kuga H., and Sato K. 1991. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res, 51, 4187-4191.
12. Kurita A., Kado S., Kaneda N., Onoue M., Hashimoto S., and Yokokura T. 2003. Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion. Cancer Chemother Pharmacol, 52, 349-360.
13. Kurita A., Kado S., Kaneda N., Onoue M., Hashimoto S., and Yokokura T. 2000. Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats. Cancer Chemother Pharmacol, 46, 211-220.
14. Lindsay G. K., Roslansky P. F., and Novitsky T. J. 1989. Single-step, chromogenic Limulus amebocyte lysate assay for endotoxin. J Clin Microbiol, 27, 947-951.
15. Pizzolato J. F. and Saltz L. B. 2003. The camptothecins. Lancet, 361, 2235-2242.
16. Roth R. I., Levin F. C., and Levin J. 1990. Optimization of detection of bacterial endotoxin in plasma with the Limulus test. J Lab Clin Med, 116, 153-161.
17. Rothenberg M. L., Eckardt J. R., Kuhn J. G., Burris H. A., 3rd, Nelson J., Hilsenbeck S. G., Rodriguez G. I., Thurman A. M., Smith L. S., Eckhardt S. G., Weiss G. R., Elfring G. L., Rinaldi D. A., Schaaf L. J., and Von Hoff D. D. 1996. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol, 14, 1128-1135.
18. Saliba F., Hagipantelli R., Misset J. L., Bastian G., Vassal G., Bonnay M., Herait P., Cote C., Mahjoubi M., Mignard D., and Cvitkovic E. 1998. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol, 16, 2745-2751.
19. Smith P. K., Krohn R. I., Hermanson G. T., Mallia A. K., Garter F. H., Provenzano M. D., Fujimoto E. K., Goeke N. M., Olson B. J., and Klenk D. C. 1985. Measurement of protein using bicinchoninic acid. Anal Biochem, 150, 76-85.
20. Stewart L., Redinbo M. R., Qiu X., Hol W. G., and Champoux J. J. 1998. A model for the mechanism of human topoisomerase I. Science, 279, 1534-1541.
21. Tonini G., Santini D., Vincenzi B., Borzomati D., Dicuonzo G., La Cesa A., Onori N., and Coppola R. 2002. Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients. J Biol Regul Homeost Agents, 16, 105-109.
22. Trifan O. C., Durham W. F., Salazar V. S., Horton J., Levine B. D., Zweifel B. S., Davis T. W., and Masferrer J. L. 2002. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res, 62, 5778-5784.
23. TsujI E., Hiki N., Nomura S., Fukushima R., Kojima J., Ogawa T., Mafune K., Mimura Y., and Kaminishi M. 2003. Simultaneous onset of acute inflammatory response, sepsis-like symptoms and intestinal mucosal injury after cancer chemotherapy. Int J Cancer., 107, 303-308.
24. Wang C. Z., Basila D., Aung H. H., Mehendale S. R., Chang W. T., McEntee E., Guan X., and Yuan C. S. 2005. Effects of Ganoderma lucidum extract on chemotherapy-induced nausea and vomiting in a rat model. Am J Chin Med, 33, 807-815.
25. Yang X. X., Hu Z. P., Chan S. Y., Goh B. C., Chan E., Duan W., and Zhou S. F. 2005. Novel agents that potentially inhibit CPT-11-induced diarrhea. Curr Med Chem, 12, 763-781.